-
HCA Healthcare, Inc. 2nd Quarter 2021 Earnings Conference Call
HCA Healthcare, Inc. 2nd Quarter 2021 Earnings Conference Call
Share
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) announces the following Webcast:
What: HCA Healthcare, Inc. 2Q Earnings Release Call
When: Tuesday, July 20, 2021 at 9:00 am central (10:00 am eastern)
How: Live Audio over the Internet:
https://investor.hcahealthcare.com/events-and-presentations/default.aspx
If you are unable to listen during the live webcast, the call will be archived on the web site https://investor.hcahealthcare.com/events-and-presentations/default.aspx.
Contacts
Mark Kimbrough
Vice President, Investor Relations
615-344-2688
mark.kimbrough@hcahealthcare.com
Paula Vaughn
615-344-2068
paula.vaughn@hcahealthcare.com.
More News From HCA Healthcare
HCA Healthcare, Inc. 2nd Quarter 2026 Earnings Conference Call
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) announces the following Webcast: What: HCA Healthcare, Inc. 2Q 2026 Earnings Call When: Friday, July 24, 2026, at 9:00 AM Central (10:00 AM Eastern) How: Live Audio over the Internet: https://investor.hcahealthcare.com/events-and-presentations/default.aspx Contact: Frank Morgan, 615-344-2688, Vice President, Investor Relations, frank.morgan@hcahealthcare.com If you are unable to listen during the live webcast, the call will be...
HCA Healthcare Previews Second Quarter 2026 Results
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced preliminary financial and operating results for the second quarter ended June 30, 2026. The preliminary financial and operating results are subject to finalization of the Company's quarterly financial and accounting procedures. HCA anticipates revenues in the second quarter of 2026 to approximate $20.230 billion, compared to $18.605 billion in the second quarter of 2025. Net income attributable to HCA Healthcare...
HCA Healthcare Announces New England Journal of Medicine Study Highlighting Advances in CRISPR-based Therapy for Children
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced new research published in The New England Journal of Medicine (NEJM) demonstrating promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. Sickle cell disease and beta thalassemia are inherited blood disorders that can cause serious, lifelong complications b...
